Merus

Merus EV/Revenue

Delisted

The EV/Revenue (Enterprise Value to Revenue) of Merus (MRUS) as of Nov 16, 2026 is 180.31. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 162.56 — a change of 10.92% (higher).

EV/Revenue

180.31

YoY

10.92%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Merus is 2024 180.31 . EV/Revenue (Enterprise Value to Revenue) of Merus was 2023 162.56 . It decreases by 10.92% higher compared to the previous year.

The Merus EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2017
301.43 USD
Jan 1, 2018
197.33 USD
Jan 1, 2019
237.31 USD
Jan 1, 2020
270.02 USD
Jan 1, 2021
148.70 USD
Jan 1, 2022
168.29 USD
Jan 1, 2023
162.56 USD
Jan 1, 2024
180.31 USD
The Merus EV/Revenue history
YEAREV/RevenueYoY
180.31+10.92%
162.56-3.41%
168.29+13.17%
148.70-44.93%
270.02+13.78%
237.31+20.26%
197.33-34.54%
301.43-88.82%
2,695.97-24.37%
3,564.85-31.94%
5,237.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merus Stock analysis

What does Merus do? Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merus stock

EV/Revenue (Enterprise Value to Revenue) of Merus is 180.31 in 2024.

EV/Revenue (Enterprise Value to Revenue) of Merus changed from 162.56 to 180.31, representing a 10.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Merus since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Merus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Merus

All Key Metrics — Merus